Current Issue


Rivaroxaban associated with increased risk for GI bleeding compared to other DOACs

A study in Iceland of direct oral anticoagulants (DOACs) found a higher risk for overall and major GI bleeding with rivaroxaban than with either apixaban or dabigatran.

Metabolic syndrome may be linked to pancreatic cancer risk

A nationwide cohort study in Korea found that risk for pancreatic cancer decreased in patients whose metabolic syndrome improved versus persisted over time.

NAFLD progression associated with increased mortality risk

Patients with stage F4 nonalcoholic fatty liver disease (NAFLD) have significantly increased risk for liver-related complications, type 2 diabetes, and all-cause mortality compared to those with earlier stages, an observational prospective study found.

MKSAP Quiz: Hepatocellular carcinoma surveillance after HCV treatment

This month's quiz asks readers to determine the most appropriate biannual surveillance modality for a 62-year-old patient with compensated cirrhosis who was treated for hepatitis C virus (HCV) infection six months ago.

Spotlight on COVID-19 vaccines in IBD

Recent research looked at the response to mRNA COVID-19 vaccines among patients with inflammatory bowel disease (IBD), as well as examined COVID-19 vaccine uptake and offered ways to address vaccine hesitancy in this population.

Immediate catheter drainage not superior to delayed in infected necrotizing pancreatitis

A trial found that catheter drainage within 24 hours was associated with similar complications but a greater number of interventions compared to drainage that was delayed until the development of walled-off necrosis.

Vonoprazan-containing therapy has an H pylori eradication rate >90% and increases eradication vs. standard triple therapy

Results of a systematic review and network meta-analysis support a shift toward a susceptibility-based approach to Helicobacter pylori infection based on principles of antimicrobial stewardship, an ACP Journal Club commentary noted.